Roche signs $1.16B obesity drug deal with China’s Rona Therapeutics

What happened: Roche (RHHBY) signed an exclusive worldwide licensing agreement with China's Rona Therapeutics for an experimental obesity drug candidate. Key numbers: Deal worth up to $1.16B, with a $100M upfront payment to Rona. Why it matters: The agreement expands Roche's obesity drug pipeline through a licensing deal with a Chinese biotechnology company.

Roche (RHHBY) signed an exclusive worldwide licensing agreement with China's Rona Therapeutics for an experimental obesity drug candidate.

The agreement expands Roche's obesity drug pipeline through a licensing deal with a Chinese biotechnology company.